Johnson & Johnson: The Behemoth Continues Defying Gravity
Johnson & Johnson's Second Quarter: Flight of
the Bumblebee Continues
Johnson & Johnson: Second Quarter 2014
• Consumer goods up 2.4%
• Devices and diagnostics up
• Pharmaceuticals rose a
stunning 21.1% -- 36.6% in the
• Overall 9.1% increase in sales,
and a 13.5% EPS boost
• Firing on all cylinders
Johnson & Johnson: Hepatitis C Virus
• Sales reached $831 million despite just 7
months on the market.
• Off-label use in combination with Gilead's
Sovaldi largely responsible for the
company's overall upside surprise.
• Upcoming combination therapies could
make Olysio obsolite
• Combos under review from:
– Gilead Sciences
• Combos in late stage development from:
– Bristol-Myers Squibb
Johnson & Johnson: Next-Gen Blood Thinner
• First once-daily oral anticoagulant
approved in US.
• Second quarter sales rose a whopping
91% year-on-year to $361 million.
• Safety issues for Boehringer
Ingelheim's Pradaxa and a
dissapointing Eliquis launch from
partners Bristol-Myers Squibb are
playing out well for Xarelto.
• Partnership with Bayer limits share of
Johnson & Johnson: Type-2 Diabetes
• First-in-class all oral type-2 diabetes
therapy to win FDA approval.
• Treats patients no longer
responsive to insulin.
• Listed as major growth driver in
earnings release, but sales recorded
in "other" category, which fell 1.8%
year-on-year to $698 million.
• AstraZeneca's recently approved
Forxiga and concerns over urinary
Johnson & Johnson: Oncology
• Developed in partnership with
Pharmacyclics, this program highlights
the company's successful partnering
• Blockbuster opportunity from chronic
lymphoid leukemia indication.
• Pharmacyclics reported net product
revenue of $56.2 during latest quarter.
• Beat Glaxo's Arzerra in a head-to-head
• Gilead's idelalisib -- currently under FDA
review -- could threaten growth going
Johnson & Johnson: A Fool Looks Ahead
• Olysio's contribution likely
to decline sharply in 2015
• Invokana, Imbruvica, and
even Xarelto still in the
early stage of their growth
• Upcoming patent
expirations for Remicade
might be aleviated by
regulartory hurdles for
more complex injectible
Devices and diagnostics:
• Cost cutting initiatives could
keep growth reletively slow
• Baby care, skin care, and
over the counter product
sales exhibiting strong
A coming blockbuster that
will make every biotech
For more, click here!